6 / 17
Page 44
conferenceseries
.com
Volume 8
Journal of Clinical & Experimental Pathology
Pathology Summit 2018
July 02-03, 2018
July 02-03, 2018 Bangkok, Thailand
15
th
Global Experts Meeting on
Pathology and Laboratory Medicine
Renalase and Dopamine study in chronic renal failure patients
Hoda Ali Mohamed El-Attar and Gaber E W
Alexandria University, Egypt
Introduction:
The human kidney releases a monoamine oxidase, renalase, which was discovered in 2005, to the blood
stream to regulate the blood pressure. Renalase decreases systemic pressure by metabolizing the circulating catecholamines.
Hypertension is highly prevalent in patients with diabetic nephropathy which is one of the leading causes (about 80%) of
chronic kidney disease and end-stage kidney disease. When considered in isolation, hypertension and diabetes are associated
with increased risk of the development of cardiovascular and renal complications. It is recognized that sympathetic nervous
activation and stimulation of the rennin-angiotensin-aldosterone are involved. The dopaminergic and rennin-angiotensin
systems interact to regulate the blood pressure. The vasodilator, Dopamine, counteracts angiotensin receptors in the paracrine
regulation of renal sodium transport. Levels of renalase that metabolize catecholamines are decreased in chronic kidney
disease and the plasma concentration of renalase is markedly reduced in patients with ESRD. Chronic kidney disease is often
characterized by the presence of sympathetic hyperactivity, which contribute to the development of other forms of organ
damage independent of its effect on blood pressure. It is associated with heart failure, arrhythmias and atherogenesis. Decrease
renalase level plays an important role in cardiovascular pathology. Chronic kidney disease leads to an 18-fold increase in
cardiovascular complications not fully explained by traditional risk factors. Preventing the progression of renal failure and
reducing cardiovascular risk of uraemic patients are major challenges for nephrologists. Interference with sympathetic over
activity may provide a new therapeutic avenue to follow in clinical medicine.
Aim:
To assess the relationship between Dopamine and Renalase in Egyptian type-2 diabetic patients in the presence and
absence of diabetic nephropathy.
Subjects & Methods:
80 subjects were divided in three groups as follow: Group-1: 10 control healthy volunteers, Group-2: 60
type-2 diabetic patients and Group-3: Type-2 diabetic patients on maintenance hemodialysis.
Results:
Significant increase in blood pressure, both systolic and diastolic in diabetic patients and diabetic patients on
maintenance hemodialysis as compared to controls. No significant change in Dopamine level in between the studied groups.
No significant change in Renalase in type-2 diabetic patients but significant increase in renalase level in diabetic patients
on maintenance hemodialysis as compared to controls (p=0.000) also to diabetic patients (p=0.004). There was significant
correlation between Renalase and Dopamine (r=0.261, p=0.022) and Renalase and diastolic blood pressure (r=0.243, p=0.041)
in diabetic patients.
Conclusion:
Renalase is an attractive replacement therapeutic modality in hypertensive type-2 diabetic patients in order to
prolong the interval between early chronic and end-stage renal failure.
hoda.ali55151@yahoo.comJ Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C2-049